緑内障市場：タイプ、診断方法、治療、エンドユーザー、年齢層別-2025年～2030年の世界予測

緑内障市場は、2023年に72億3,000万米ドルと評価され、2024年には76億米ドルに達すると予測され、CAGR 5.56％で成長し、2030年には105億6,000万米ドルに達すると予測されています。

世界的に不可逆的な失明の主要原因であるKEYWORDは、高齢化人口の増加と有病率の増加により、広範な市場調査が求められています。この市場には、緑内障の管理・治療を目的とした診断機器、手術機器、医薬品、治療ソリューションなど多様なものが含まれます。高度な緑内障治療の必要性は、視力喪失を防ぐ必要性によって強調され、患者の生活の質を大幅に向上させます。アプリケーションは臨床現場、研究機関、ヘルスケア施設に及び、手術の進歩、革新的なドラッグデリバリーシステム、眼圧や網膜の健康状態をより良く管理するための診断ツールの強化などが活用されています。最終用途の範囲は広く、病院、眼科専門クリニック、在宅医療環境などが含まれ、個別化医療への動向も高まっています。市場成長は、手術機器や診断機器の技術的進歩、地域社会への積極的な働きかけによる患者の意識向上、研究や予防措置を後押しする政府の取り組みなどの要因に大きく影響されています。新たな機会は、低侵襲手術技術、AIおよびIoTベースの診断ツール、個別化治療アプローチの開発にあります。しかし、市場成長は、高額な治療費、低所得地域における公平なアクセスの欠如、規制上のハードルなどの限界に直面しています。さらに、緑内障の複雑な病態生理とその無症候性は、早期診断と治療のアドヒアランスに課題をもたらします。遺伝子治療、神経保護、徐放性ドラッグデリバリーシステム、遠隔医療ベースの患者管理などの分野でイノベーションを起こせば、競争優位に立てる可能性があります。市場の性質はダイナミックで、バイオテクノロジー企業、ヘルスケアプロバイダー、学術機関のコラボレーションを促進します。企業は、潜在的な成長の可能性をつかみ、世界規模での経営を改善するために、共同研究、新たなデジタルヘルスソリューションへの投資、未開拓市場への進出に注力することが推奨されます。

市場力学：急速に進化する緑内障市場の主要市場インサイトを公開

緑内障市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 市場拡大に寄与する低侵襲手術の採用増加（緑内障）
  • 緑内障治療における併用療法の利用拡大が市場開拓を促進
  • 緑内障管理のための遠隔医療および遠隔モニタリングサービスの拡大による市場の拡大
  • 緑内障用の新規ドラッグデリバリーシステムの開発による患者のコンプライアンスと治療成績の向上
• 市場抑制要因
  • 新しい緑内障治療のイントロダクション影響する規制上の課題と承認プロセスの遅れ
  • 緑内障に関する認識や教育の不足による診断や治療の遅れ
• 市場機会
  • 高度な遺伝子治療と個別化医療アプローチによる緑内障治療の変革
  • 緑内障の早期発見と早期管理を強化するための人工知能と機械学習の活用
  • 緑内障患者の予後と回復を改善するための、革新的で侵襲性の低い手術技術の開発
• 市場の課題
  • 緑内障症状の早期発見に関する一般住民の認識と教育の欠如
  • 地方や低開発地域における緑内障専門医療の利用可能性とアクセス性の制限

ポーターの5つの力：緑内障市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：緑内障市場における外部からの影響の把握

外部マクロ環境要因は、緑内障市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析緑内障市場における競合情勢の把握

緑内障市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス緑内障市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、緑内障市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨緑内障市場における成功への道筋を描く

緑内障市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 低侵襲手術の導入増加が市場拡大に貢献
    • 治療における併用療法の利用増加が市場開拓を促進
    • 遠隔医療および遠隔モニタリングサービスの拡大により、市場へのリーチを拡大
    • 患者のコンプライアンスと転帰を改善する新しいドラッグデリバリーシステムの開発
  • 抑制要因
    • 規制上の課題と遅い承認プロセスが新しい緑内障治療法のイントロダクション影響を及ぼしている
    • 緑内障に関する認識と教育の欠如が診断と治療の遅れにつながる
  • 機会
    • 先進的な遺伝子治療と個別化医療アプローチによる緑内障治療の革新
    • 人工知能と機械学習を活用して、早期の緑内障検出と管理を強化する
    • 患者様の転帰と回復を改善するために、革新的で低侵襲性の外科手術技術を開発する
  • 課題
    • 一般の人々の間での緑内障症状の早期発見に関する認識と教育の欠如
    • 農村地域や発展途上地域では専門的なケアが利用しにくく、アクセスも困難
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 緑内障市場：タイプ別

• 角度閉鎖緑内障
• ノーマルテンション緑内障
• プライマリオープンアングル緑内障

第7章 緑内障市場：診断方法別

• 隅角鏡検査
• 眼圧測定
• 視野検査

第8章 緑内障市場：治療別

• レーザー治療
  • アルゴンレーザー線維柱帯形成術
  • 選択的レーザー線維柱帯形成術
• 薬物治療
  • アルファ作動薬
  • ベータ遮断薬
  • 炭酸脱水酵素阻害剤
  • プロスタグランジン類似体
• 手術
  • ドレナージインプラント
  • 低侵襲緑内障手術
  • 線維柱帯切除術

第9章 緑内障市場：エンドユーザー別

• 外来手術センター
• 病院
• 眼科クリニック
• 研究機関

第10章 緑内障市場：年齢層別

• 成人用
• 高齢者
• 小児科

第11章 南北アメリカの緑内障市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の緑内障市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの緑内障市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 1. Aerie Pharmaceuticals
• 2. Alcon
• 3. Allergan
• 4. Allergan (acquired by Abbvie)
• 5. Bausch Health
• 6. EyeGate Pharmaceuticals
• 7. Eyenovia
• 8. Glaukos Corporation
• 9. Inotek Pharmaceuticals
• 10. Johnson & Johnson
• 11. Merck
• 12. Nicox
• 13. Novartis
• 14. Pfizer
• 15. Regeneron Pharmaceuticals
• 16. Roche
• 17. Sanofi
• 18. Santen Pharmaceutical
• 19. Teva Pharmaceutical
• 20. Valeant Pharmaceuticals International

LIST OF FIGURES

• FIGURE 1. GLAUCOMA MARKET RESEARCH PROCESS
• FIGURE 2. GLAUCOMA MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GLAUCOMA MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GLAUCOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GLAUCOMA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GLAUCOMA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GLAUCOMA MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GLAUCOMA MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL GLAUCOMA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL GLAUCOMA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL GLAUCOMA MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL GLAUCOMA MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES GLAUCOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES GLAUCOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. GLAUCOMA MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. GLAUCOMA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GLAUCOMA MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GLAUCOMA MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GLAUCOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GLAUCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GLAUCOMA MARKET DYNAMICS
• TABLE 7. GLOBAL GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GLAUCOMA MARKET SIZE, BY ANGLE-CLOSURE GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GLAUCOMA MARKET SIZE, BY NORMAL-TENSION GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GLAUCOMA MARKET SIZE, BY PRIMARY OPEN-ANGLE GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GLAUCOMA MARKET SIZE, BY GONIOSCOPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GLAUCOMA MARKET SIZE, BY TONOMETRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GLAUCOMA MARKET SIZE, BY VISUAL FIELD TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GLAUCOMA MARKET SIZE, BY LASER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GLAUCOMA MARKET SIZE, BY ARGON LASER TRABECULOPLASTY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GLAUCOMA MARKET SIZE, BY SELECTIVE LASER TRABECULOPLASTY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL GLAUCOMA MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL GLAUCOMA MARKET SIZE, BY ALPHA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL GLAUCOMA MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL GLAUCOMA MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL GLAUCOMA MARKET SIZE, BY PROSTAGLANDIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL GLAUCOMA MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL GLAUCOMA MARKET SIZE, BY DRAINAGE IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL GLAUCOMA MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL GLAUCOMA MARKET SIZE, BY TRABECULECTOMY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL GLAUCOMA MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL GLAUCOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL GLAUCOMA MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL GLAUCOMA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL GLAUCOMA MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL GLAUCOMA MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL GLAUCOMA MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS GLAUCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 65. CANADA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. CANADA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 67. CANADA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 68. CANADA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 69. CANADA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 70. CANADA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 71. CANADA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. CANADA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 81. UNITED STATES GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES GLAUCOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 90. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 94. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 98. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 99. AUSTRALIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. AUSTRALIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 101. AUSTRALIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 102. AUSTRALIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 103. AUSTRALIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 104. AUSTRALIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 105. AUSTRALIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. AUSTRALIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 107. CHINA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. CHINA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 109. CHINA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 110. CHINA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 111. CHINA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 112. CHINA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 113. CHINA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. CHINA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 115. INDIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. INDIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 117. INDIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 118. INDIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 119. INDIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 120. INDIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 121. INDIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. INDIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 123. INDONESIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. INDONESIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 125. INDONESIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 126. INDONESIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 127. INDONESIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 128. INDONESIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 129. INDONESIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. INDONESIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 131. JAPAN GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. JAPAN GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 133. JAPAN GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 134. JAPAN GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 135. JAPAN GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 136. JAPAN GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 137. JAPAN GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. JAPAN GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 139. MALAYSIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. MALAYSIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 141. MALAYSIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 142. MALAYSIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 143. MALAYSIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 144. MALAYSIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 145. MALAYSIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. MALAYSIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 147. PHILIPPINES GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. PHILIPPINES GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 149. PHILIPPINES GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 150. PHILIPPINES GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 151. PHILIPPINES GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 152. PHILIPPINES GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 153. PHILIPPINES GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. PHILIPPINES GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 155. SINGAPORE GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 156. SINGAPORE GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 157. SINGAPORE GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 158. SINGAPORE GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 159. SINGAPORE GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 160. SINGAPORE GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 161. SINGAPORE GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. SINGAPORE GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH KOREA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH KOREA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH KOREA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH KOREA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH KOREA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH KOREA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH KOREA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH KOREA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 171. TAIWAN GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 172. TAIWAN GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 173. TAIWAN GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 174. TAIWAN GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 175. TAIWAN GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 176. TAIWAN GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 177. TAIWAN GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. TAIWAN GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 179. THAILAND GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 180. THAILAND GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 181. THAILAND GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 182. THAILAND GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 183. THAILAND GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 184. THAILAND GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 185. THAILAND GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. THAILAND GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 187. VIETNAM GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 188. VIETNAM GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 189. VIETNAM GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 190. VIETNAM GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 191. VIETNAM GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 192. VIETNAM GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 193. VIETNAM GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. VIETNAM GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 204. DENMARK GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 205. DENMARK GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 206. DENMARK GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 207. DENMARK GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 208. DENMARK GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 209. DENMARK GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 210. DENMARK GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 211. DENMARK GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 212. EGYPT GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 213. EGYPT GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 214. EGYPT GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 215. EGYPT GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 216. EGYPT GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 217. EGYPT GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 218. EGYPT GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 219. EGYPT GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 220. FINLAND GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 221. FINLAND GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 222. FINLAND GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 223. FINLAND GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 224. FINLAND GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 225. FINLAND GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 226. FINLAND GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 227. FINLAND GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 228. FRANCE GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 229. FRANCE GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 230. FRANCE GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 231. FRANCE GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 232. FRANCE GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 233. FRANCE GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 234. FRANCE GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 235. FRANCE GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 236. GERMANY GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 237. GERMANY GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 238. GERMANY GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 239. GERMANY GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 240. GERMANY GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 241. GERMANY GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 242. GERMANY GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 243. GERMANY GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 244. ISRAEL GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 245. ISRAEL GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 246. ISRAEL GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 247. ISRAEL GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 248. ISRAEL GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 249. ISRAEL GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 250. ISRAEL GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 251. ISRAEL GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 252. ITALY GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 253. ITALY GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 254. ITALY GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 255. ITALY GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 256. ITALY GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 257. ITALY GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 258. ITALY GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 259. ITALY GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 260. NETHERLANDS GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 261. NETHERLANDS GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 262. NETHERLANDS GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 263. NETHERLANDS GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 264. NETHERLANDS GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 265. NETHERLANDS GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 266. NETHERLANDS GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 267. NETHERLANDS GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 268. NIGERIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 269. NIGERIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 270. NIGERIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 271. NIGERIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 272. NIGERIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 273. NIGERIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 274. NIGERIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 275. NIGERIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 276. NORWAY GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 277. NORWAY GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 278. NORWAY GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 279. NORWAY GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 280. NORWAY GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 281. NORWAY GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 282. NORWAY GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 283. NORWAY GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 284. POLAND GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 285. POLAND GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 286. POLAND GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 287. POLAND GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 288. POLAND GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 289. POLAND GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 290. POLAND GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 291. POLAND GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 292. QATAR GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 293. QATAR GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 294. QATAR GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 295. QATAR GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 296. QATAR GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 297. QATAR GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 298. QATAR GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 299. QATAR GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 300. RUSSIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 301. RUSSIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 302. RUSSIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 303. RUSSIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 304. RUSSIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 305. RUSSIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 306. RUSSIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 307. RUSSIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 308. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 309. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 310. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 311. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 312. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 313. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 314. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 315. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 316. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 317. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 318. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 319. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 320. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 321. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 322. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 323. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 324. SPAIN GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 325. SPAIN GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 326. SPAIN GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 327. SPAIN GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 328. SPAIN GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 329. SPAIN GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 330. SPAIN GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 331. SPAIN GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 332. SWEDEN GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 333. SWEDEN GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 334. SWEDEN GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 335. SWEDEN GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 336. SWEDEN GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 337. SWEDEN GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 338. SWEDEN GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 339. SWEDEN GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 340. SWITZERLAND GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 341. SWITZERLAND GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 342. SWITZERLAND GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 343. SWITZERLAND GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 344. SWITZERLAND GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 345. SWITZERLAND GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 346. SWITZERLAND GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 347. SWITZERLAND GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 348. TURKEY GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 349. TURKEY GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 350. TURKEY GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 351. TURKEY GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 352. TURKEY GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 353. TURKEY GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 354. TURKEY GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 355. TURKEY GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 356. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 357. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 358. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 359. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 360. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 361. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 362. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 363. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 364. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 365. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
• TABLE 366. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 367. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 368. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 369. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 370. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 371. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 372. GLAUCOMA MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 373. GLAUCOMA MARKET, FPNV POSITIONING MATRIX, 2023

The Glaucoma Market was valued at USD 7.23 billion in 2023, expected to reach USD 7.60 billion in 2024, and is projected to grow at a CAGR of 5.56%, to USD 10.56 billion by 2030.

Glaucoma, a leading cause of irreversible blindness globally, demands extensive market research due to the growing aging population and increasing prevalence of the disease. The scope of this market includes a diverse array of diagnostic equipment, surgical devices, pharmaceuticals, and therapeutic solutions aimed at managing and treating glaucoma. The necessity for advanced glaucoma treatments is underscored by the need to prevent vision loss, thus ensuring a substantial quality of life for patients. Applications span clinical settings, research institutions, and healthcare facilities, utilizing surgical advancements, innovative drug delivery systems, and enhanced diagnostic tools to better manage intraocular pressure and retinal health. The end-use scope is broad, encompassing hospitals, specialized ophthalmology clinics, and home care settings, with an increasing trend toward personalized medicine. Market growth is significantly influenced by factors such as technological advancements in surgical and diagnostic devices, higher awareness among patients due to robust community outreach, and government initiatives to boost research and preventive measures. Emerging opportunities lie in developing minimally invasive surgical techniques, AI and IoT-based diagnostic tools, and personalized therapeutic approaches. However, market growth faces limitations such as high costs of treatment, lack of equitable access in low-income regions, and regulatory hurdles. Moreover, complex pathophysiology of glaucoma and its asymptomatic nature pose challenges in early diagnosis and treatment adherence. Innovating in areas like gene therapy, neuroprotection, sustained-release drug delivery systems, and telemedicine-based patient management could provide a competitive edge. The market's nature is dynamic, fostering collaboration between biotech firms, healthcare providers, and academic institutions. Businesses are recommended to focus on collaborative research, investing in emerging digital health solutions, and expanding into untapped markets to seize latent growth potential and improve glaucoma management on a global scale.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Glaucoma Market

The Glaucoma Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising adoption of minimally invasive glaucoma surgeries contributing to market expansion
  • Increasing utilization of combination therapies in glaucoma treatment fostering market development
  • Expansion of telemedicine and remote monitoring services for glaucoma management enhancing market reach
  • Development of novel drug delivery systems for glaucoma improving patient compliance and outcomes
• Market Restraints
  • Regulatory challenges and slow approval process affecting the introduction of new glaucoma therapies
  • Lack of awareness and education about glaucoma leading to delayed diagnosis and treatment
• Market Opportunities
  • Revolutionizing glaucoma treatment through advanced gene therapy and personalized medicine approaches
  • Leveraging artificial intelligence and machine learning to enhance early glaucoma detection and management
  • Developing innovative and less-invasive surgical techniques for glaucoma patients to improve outcomes and recovery
• Market Challenges
  • Lack of awareness and education on early detection of glaucoma symptoms among the general population
  • Limited availability and accessibility of specialized glaucoma care in rural and underdeveloped regions

Porter's Five Forces: A Strategic Tool for Navigating the Glaucoma Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Glaucoma Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Glaucoma Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Glaucoma Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Glaucoma Market

A detailed market share analysis in the Glaucoma Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Glaucoma Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Glaucoma Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Glaucoma Market

A strategic analysis of the Glaucoma Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Glaucoma Market, highlighting leading vendors and their innovative profiles. These include Aerie Pharmaceuticals, Alcon, Allergan, Allergan (acquired by Abbvie), Bausch Health, EyeGate Pharmaceuticals, Eyenovia, Glaukos Corporation, Inotek Pharmaceuticals, Johnson & Johnson, Merck, Nicox, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi, Santen Pharmaceutical, Teva Pharmaceutical, and Valeant Pharmaceuticals International.

Market Segmentation & Coverage

This research report categorizes the Glaucoma Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Angle-Closure Glaucoma, Normal-Tension Glaucoma, and Primary Open-Angle Glaucoma.
• Based on Diagnosis Method, market is studied across Gonioscopy, Tonometry, and Visual Field Test.
• Based on Treatment, market is studied across Laser Treatment, Medication, and Surgery. The Laser Treatment is further studied across Argon Laser Trabeculoplasty and Selective Laser Trabeculoplasty. The Medication is further studied across Alpha Agonists, Beta Blockers, Carbonic Anhydrase Inhibitors, and Prostaglandin Analogs. The Surgery is further studied across Drainage Implants, Minimally Invasive Glaucoma Surgery, and Trabeculectomy.
• Based on End-User, market is studied across Ambulatory Surgery Centers, Hospitals, Ophthalmic Clinics, and Research Institutes.
• Based on Age Group, market is studied across Adult, Geriatric, and Pediatric.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising adoption of minimally invasive glaucoma surgeries contributing to market expansion
    • 5.1.1.2. Increasing utilization of combination therapies in glaucoma treatment fostering market development
    • 5.1.1.3. Expansion of telemedicine and remote monitoring services for glaucoma management enhancing market reach
    • 5.1.1.4. Development of novel drug delivery systems for glaucoma improving patient compliance and outcomes
  • 5.1.2. Restraints
    • 5.1.2.1. Regulatory challenges and slow approval process affecting the introduction of new glaucoma therapies
    • 5.1.2.2. Lack of awareness and education about glaucoma leading to delayed diagnosis and treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Revolutionizing glaucoma treatment through advanced gene therapy and personalized medicine approaches
    • 5.1.3.2. Leveraging artificial intelligence and machine learning to enhance early glaucoma detection and management
    • 5.1.3.3. Developing innovative and less-invasive surgical techniques for glaucoma patients to improve outcomes and recovery
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of awareness and education on early detection of glaucoma symptoms among the general population
    • 5.1.4.2. Limited availability and accessibility of specialized glaucoma care in rural and underdeveloped regions
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Glaucoma Market, by Type

• 6.1. Introduction
• 6.2. Angle-Closure Glaucoma
• 6.3. Normal-Tension Glaucoma
• 6.4. Primary Open-Angle Glaucoma

7. Glaucoma Market, by Diagnosis Method

• 7.1. Introduction
• 7.2. Gonioscopy
• 7.3. Tonometry
• 7.4. Visual Field Test

8. Glaucoma Market, by Treatment

• 8.1. Introduction
• 8.2. Laser Treatment
  • 8.2.1. Argon Laser Trabeculoplasty
  • 8.2.2. Selective Laser Trabeculoplasty
• 8.3. Medication
  • 8.3.1. Alpha Agonists
  • 8.3.2. Beta Blockers
  • 8.3.3. Carbonic Anhydrase Inhibitors
  • 8.3.4. Prostaglandin Analogs
• 8.4. Surgery
  • 8.4.1. Drainage Implants
  • 8.4.2. Minimally Invasive Glaucoma Surgery
  • 8.4.3. Trabeculectomy

9. Glaucoma Market, by End-User

• 9.1. Introduction
• 9.2. Ambulatory Surgery Centers
• 9.3. Hospitals
• 9.4. Ophthalmic Clinics
• 9.5. Research Institutes

10. Glaucoma Market, by Age Group

• 10.1. Introduction
• 10.2. Adult
• 10.3. Geriatric
• 10.4. Pediatric

11. Americas Glaucoma Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Glaucoma Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Glaucoma Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Aerie Pharmaceuticals
• 2. Alcon
• 3. Allergan
• 4. Allergan (acquired by Abbvie)
• 5. Bausch Health
• 6. EyeGate Pharmaceuticals
• 7. Eyenovia
• 8. Glaukos Corporation
• 9. Inotek Pharmaceuticals
• 10. Johnson & Johnson
• 11. Merck
• 12. Nicox
• 13. Novartis
• 14. Pfizer
• 15. Regeneron Pharmaceuticals
• 16. Roche
• 17. Sanofi
• 18. Santen Pharmaceutical
• 19. Teva Pharmaceutical
• 20. Valeant Pharmaceuticals International